218 related articles for article (PubMed ID: 32512287)
1. Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran.
Sahraian MA; Azimi A; Navardi S; Rezaeimanesh N; Naser Moghadasi A
Mult Scler Relat Disord; 2020 Sep; 44():102245. PubMed ID: 32512287
[No Abstract] [Full Text] [Related]
2. Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder.
Creed MA; Ballesteros E; Jr LJG; Imitola J
Mult Scler Relat Disord; 2020 Sep; 44():102199. PubMed ID: 32554285
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
[TBL] [Abstract][Full Text] [Related]
4. Neuromyelitis optica spectrum disorder and menstruation.
Badihian S; Manouchehri N; Mirmosayyeb O; Ashtari F; Shaygannejad V
Rev Neurol (Paris); 2018 Dec; 174(10):716-721. PubMed ID: 30049560
[TBL] [Abstract][Full Text] [Related]
5. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
Ashtari F; Mehdipour R; Shaygannejad V; Mansourian M
Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
[TBL] [Abstract][Full Text] [Related]
6. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
Wallach AI; Tremblay M; Kister I
Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
[TBL] [Abstract][Full Text] [Related]
7. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
8. Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab.
Shidahara K; Hayashi K; Sada KE; Hiramatsu S; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
Lupus; 2018 Jul; 27(8):1374-1377. PubMed ID: 29498304
[TBL] [Abstract][Full Text] [Related]
9. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder.
Lin J; Li X; Xue B; Tong Q; Chen Z; Zhu W; Li J; Xia J
J Neuroimmunol; 2018 Apr; 317():1-4. PubMed ID: 29501080
[TBL] [Abstract][Full Text] [Related]
10. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
12. Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients.
Woo MS; Steins D; Häußler V; Kohsar M; Haag F; Elias-Hamp B; Heesen C; Lütgehetmann M; Schulze Zur Wiesch J; Friese MA
J Neurol; 2021 Jan; 268(1):5-7. PubMed ID: 32654064
[No Abstract] [Full Text] [Related]
13. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
15. Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
Gomez-Figueroa E; Noriega-Morales G; Casallas-Vanegas A; Zabala-Angeles I; Garcia-Estrada C; Neri D; Sarachaga AJ; Rivas-Alonso V; Corona-Vazquez T; Flores-Rivera J
Clin Neurol Neurosurg; 2020 Sep; 196():106007. PubMed ID: 32559706
[TBL] [Abstract][Full Text] [Related]
16. Isolated opsoclonus heralding neuromyelitis optica spectrum disorder.
Ghosh R; Dubey S; Ray BK; Purkait S; Pandit A; Benito-León J
J Neuroimmunol; 2020 Nov; 348():577394. PubMed ID: 32956950
[TBL] [Abstract][Full Text] [Related]
17. Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders.
Apostolos-Pereira SL; Campos Ferreira L; Boaventura M; de Carvalho Sousa NA; Joca Martins G; d'Almeida JA; Pitombeira M; Silvestre Mendes L; Fukuda T; Souza Cabeça HL; Chaves Rocha L; Santos de Oliveira B; Vieira Stella CR; Lobato de Oliveira EM; de Souza Amorim L; Ferrari de Castro A; Pereira Gomes Neto A; Diogo Silva G; Bueno L; de Morais Machado M; Castello Dias-Carneiro R; Maciel Dias R; Porto Moreira A; Piccolo A; Kuntz Grzesiuk A; Muniz A; Diniz Disserol C; Ferreira Vasconcelos C; Kaimen-Maciel D; Sisterolli Diniz D; Comini-Frota E; Coronetti Rocha F; Cruz Dos Santos GA; Dadalti Fragoso Y; Sciascia do Olival G; Ruocco HH; Siqueira HH; Sato HK; Figueiredo JA; Cortoni Calia L; Teixeira Dourado ME; Scolari L; Ribeiro Soares Neto H; Melges L; Magno Gonçalves MV; Vellutini Pimentel ML; de Castro Ribeiro M; Gurrola Arambula O; Diniz da Gama P; Leite Menon R; Barbosa Thomaz R; de Rizo Morales R; Sobreira S; Machado SN; Gonsalves Jubé Ribeiro T; Coelho Santa Rita Pereira V; Maia Costa V; da Nóbrega Junior AW; Vieira Alves-Leon S; Mamprim de Morais Perin M; Donadi E; Adoni T; Gomes S; Brito Ferreira M; Callegaro D; Mendes MF; Brum D; von Glehn F;
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34446434
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
19. Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder.
Kim SH; Hyun JW; Jeong IH; Joung A; Yeon JL; Dehmel T; Adams O; Kieseier BC; Kim HJ
J Neurol; 2015 Mar; 262(3):696-700. PubMed ID: 25559683
[TBL] [Abstract][Full Text] [Related]
20. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.
Kim SH; Hyun JW; Kim HJ
Neurochem Int; 2019 Nov; 130():104347. PubMed ID: 30513364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
